Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

Respirology

Volumn 21, Issue 8, 2016, Pages 1425-1430

  Taniguchi, Hiroyuki ^a   Xu, Zuojun ^b   Azuma, Arata ^c   Inoue, Yoshikazu ^d   Li, Huiping ^e   Fujimoto, Tsuyoshi ^f   Bailes, Zelie ^g   Schlenker Herceg, Rozsa ^h   Kim, Dong S ⁱ  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e SHANGHAI PULMONARY HOSPITAL   (China)

^f NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^g BOEHRINGER INGELHEIM LTD   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ University of Ulsan   (South Korea)

Author keywords

clinical trials; interstitial lung disease

Indexed keywords

NINTEDANIB; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG EFFECTS; DRUG MONITORING; ETHNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DRUG MONITORING; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84978924447     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12852     Document Type: Article

References (18)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–61.
3. Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr. Opin. Pulm. Med. 2013; 19: 474–9.
4. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, Wang JY, Chang YT, Chao TT, Lin HI et al. Idiopathic pulmonary fibrosis in Taiwan - a population-based study. Respir. Med. 2012; 106: 1566–74.
5. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, Bando M, Sugiyama Y, Takahashi H. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am. J. Respir. Crit. Care Med. 2014; 190: 773–9.
6. Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir. Investig. 2015; 53: 51–9.
7. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV™ (nintedanib) prescribing information, 2014. [Accessed 30 Oct 2014.] Available from URL: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf
8. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (nintedanib) summary of product characteristics, 2015. [Accessed 1 Apr 2015.] Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124
9. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68: 4774–82.
10. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014; 349: 209–20.
11. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1434–45.
12. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–82.
13. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir. Med. 1991; 85(Suppl. B): 25–31.
14. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, Lee JS, Ji W, Schwarz MI, Yang IV et al. The MUC5B promoter polymorphism is associated with IPF in a Mexican cohort but is rare among Asian ancestries. Chest 2015; 147: 460–4.
15. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir. Med. 2012; 106: 588–93.
16. Ohshimo S, Ishikawa N, Horimasu Y, Fujitaka K, Haruta Y, Murai H, Hattori N, Bonella F, Kohno N, Guzman J et al. Ethnic differences in the incidence of acute exacerbation in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2013; 187: A4345.
17. Kim DS. Acute exacerbations in patients with idiopathic pulmonary fibrosis. Clin. Chest Med. 2012; 33: 59–68.
18. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A. Effect of nintedanib in pre-specified sub-groups in INPULSIS®. Am. J. Respir. Crit. Care Med. 2016; 193: 178–85.